Inorganic nitrate as a treatment for acute heart failure: a protocol for a single center, randomized, double-blind, placebo-controlled pilot and feasibility study by Falls, R et al.
Falls et al. J Transl Med  (2017) 15:172 
DOI 10.1186/s12967-017-1271-z
PROTOCOL
Inorganic nitrate as a treatment for acute 
heart failure: a protocol for a single center, 
randomized, double-blind, placebo-controlled 
pilot and feasibility study
Roman Falls1,2, Michael Seman1,2, Sabine Braat2,4, Joshua Sortino1, Jason D. Allen1,3 and Christopher J. Neil1,2,3,5*
Abstract 
Background: Acute heart failure (AHF) is a frequent reason for hospitalization worldwide and effective treatment 
options are limited. It is known that AHF is a condition characterized by impaired vasorelaxation, together with 
reduced nitric oxide (NO) bioavailability, an endogenous vasodilatory compound. Supplementation of inorganic 
sodium nitrate  (NaNO3) is an indirect dietary source of NO, through bioconversion. It is proposed that oral sodium 
nitrate will favorably affect levels of circulating NO precursors (nitrate and nitrite) in AHF patients, resulting in reduced 
systemic vascular resistance, without significant hypotension.
Methods and outcomes: We propose a single center, randomized, double-blind, placebo-controlled pilot trial, 
evaluating the feasibility of sodium nitrate as a treatment for AHF. The primary hypothesis that sodium nitrate treat-
ment will result in increased systemic levels of nitric oxide pre-cursors (nitrate and nitrite) in plasma, in parallel with 
improved vasorelaxation, as assessed by non-invasively derived systemic vascular resistance index. Additional sur-
rogate measures relevant to the known pathophysiology of AHF will be obtained in order to assess clinical effect on 
dyspnea and renal function.
Discussion: The results of this study will provide evidence of the feasibility of this novel approach and will be of inter-
est to the heart failure community. This trial may inform a larger study.
Keywords: Heart failure, Acute heart failure, Acute decompensated heart failure, Sodium nitrate, Nitric oxide, Non-
invasive cardiovascular monitoring
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Background and rationale
Acute heart failure: incidence and current treatment
In the United States, acute heart failure (AHF), also 
known as acute decompensated heart failure, is responsi-
ble for over 1 million hospital admissions annually [1] and 
is the leading reason for hospitalization among patients 
over 65  years of age. AHF refers to the heterogeneous 
syndrome of the gradual or rapid onset of worsening 
signs and/or symptoms of heart failure [2, 3], attributed 
to fluid overload, raised ventricular filling pressures and/
or pulmonary congestion [4].
Although contemporary medical and device-based 
therapies (including non-invasive ventilation and ven-
tricular assist devices) have substantially improved the 
outlook for patients with chronic heart failure, the lack 
of established effective treatment strategies for patients 
presenting with AHF has been identified as a major need 
[5]. This, together with (i) the re-emerging role of vaso-
dilators in AHF, (ii) evidence for acutely impaired nitric 
oxide (NO) bioavailability and (iii) the potential thera-
peutic benefit of inorganic sodium nitrate, will be dis-
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Vascular resistance in the hemodynamics of AHF
A discussion of typical hemodynamic profiles in the 
spectrum of AHF presentations is crucial to understand 
the re-emerging role of vasodilators in this context. 
Patients with AHF generally present with an elevated 
pulmonary capillary wedge pressure (PCWP), result-
ing in congestion (interstitial and/or alveolar pulmonary 
edema), present in the majority of cases of AHF. On the 
other hand, cardiac output/cardiac index (CI) can vary 
substantially within the AHF population. The majority 
of AHF patients (69%) actually present with a CI in the 
normal range, as illustrated by the work of Nohria et al. 
[6]. Furthermore, the majority of patients with AHF are 
known to present with hypertension (50%), rather than 
normotension (47%) or hypotension (3%) [7]. By infer-
ence, given that such patients are typically not hyperdy-
namic, systemic vascular resistance (SVR) is likely to be 
generally and markedly elevated at the time of acute pres-
entations in this group. Elevated SVR was found to be the 
most consistent hemodynamic abnormality in a cross-
sectional study employing non-invasive cardiac output 
measurements in a large cohort of AHF patients [8].
Acute elevation of SVR has several implications in 
the context of AHF. Increased SVR would generally be 
attributed to impaired vasorelaxation (or failure of vaso-
dilation) at an arteriolar level, as a net result of neuroen-
docrine and paracrine signals, in addition to the influence 
of vasoactive drugs. Importantly, activation of the sym-
pathetic nervous system, with arteriolar vasoconstriction 
and reduced venous capacitance, is thought to promote 
the centralization of blood volume, in the genesis of pul-
monary congestion [9, 10]. The effects of high SVR on 
afterload are also likely to be crucial in the pathophysiol-
ogy of AHF, which has been conceptualized as a condi-
tion of afterload mismatch, as reviewed by Cotter et  al. 
[8, 11]. In respect to afterload, it should be noted that 
there are pulsatile and non-pulsatile elements of afterload 
and both are known to be abnormal in AHF [12, 13]. All 
of the above considerations are components of an emerg-
ing vasculocentric model of AHF [14].
Current therapeutics in AHF
The primary therapeutic objective during AHF hospitali-
zation is decongestion, whilst avoiding the complications 
of hypotension and worsening renal function (WRF). 
Currently, loop diuretic is universally recommended in 
international guidelines, with the directed use of nonin-
vasive ventilation, nitrovasodilators and inotropic sup-
port, in more severe cases [3, 15]. With the exception of 
noninvasive ventilation, this basic therapeutic tool kit has 
been consistent for over 30 years. Unfortunately, despite 
substantial effort, no novel pharmacological strategy has 
thus far been shown to be superior. Positive inotropes 
have been associated with increased mortality [16]. In 
regards to high dose intravenous organic nitrates (e.g. 
isosorbide dinitrate, glyceryltrinitrate), despite their 
availability and apparent benefit in several relatively small 
phase II studies [17–19], use is hampered by the develop-
ment of tolerance [20], as well as the generation of reac-
tive oxygen species [21] and impaired biotransformation 
in heart failure patients [22].
Several novel neurohumoral therapeutic strategies, 
including recombinant B-type natriuretic peptide infu-
sion, adenosine receptor antagonism and vasopressin 
receptor antagonism, have not demonstrated an advan-
tage over standard therapy [23–25]. Mechanical diuresis 
via ultrafiltration has likewise not demonstrated supe-
riority to standard medical diuresis, in fact demonstrat-
ing an increased incidence of adverse events [26]. More 
recently, serelaxin, a recombinant vasodilating peptide, 
has shown some promise in a study by Teerlink et  al. 
[27]. Whilst there was a significant benefit seen in dysp-
nea relief during treatment and biomarker endpoints, the 
30-day readmission rate was not reduced. Intriguingly, 
however, the mortality at 6  months was improved over 
placebo. This finding has focused interest on vasodilation 
in AHF, as well as informed a large phase III study [28].
Nitric oxide bioavailability in AHF
The normal physiology of vascular relaxation involves the 
generation of NO via endothelial nitric oxide synthase, 
from l-arginine; NO freely diffuses to adjacent smooth 
muscle cells to activate soluble guanylate cyclase (sCG), 
which induces vasorelaxation via a second messenger 
cyclic guanylate monophosphate. Heart failure is associ-
ated with decreased NO bioavailability and dysfunction 
of endothelial NOS [29]. In acute decompensation, there 
is decreased overall NO production, as reflected by a 38% 
decrease in systemic nitrate and nitrite [30]. An addi-
tional mechanism by which NOS function may be acutely 
impaired is a substantial increase in levels of circulating 
asymmetric dimethylarginine (ADMA), an endogenous 
inhibitor of NOS, which was measured simultaneously 
with reduced nitrate and nitrite levels, by Saitoh and 
colleges [30]. Thus, in the AHF context, impaired NOS 
function may be at the nexus of poor NO biosynthesis/
bioavailability and elevated SVR. Methods to therapeuti-
cally circumvent this deficiency may result in therapeutic 
benefit.
The concept of a circulating pool of inorganic nitrite 
(NO−
2
) and nitrate (NO−
3
) as an effective NO donor, 
independent of endothelial NOS function, has received 
increasing attention over the past decade [31]. Nitrite lev-
els can be increased via direct administration (e.g. intra-
venous or inhaled), or by oral intake of nitrate (typically 
in foods or as a pure compound, with a half-life of 5–6 h), 
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which is subsequently reduced in vivo, increasing plasma 
concentrations of nitrite [32] (see Fig. 1). The therapeu-
tic potential of a nitrate/nitrite supplementation strat-
egy in cardiovascular disease is underscored, when three 
additional facts are considered: (i) circulating nitrite may 
selectively donate NO to hypoxic vascular beds [33], (ii) 
repeat administration does not seem to induce tolerance 
[34], unlike the situation with organic nitrates and (iii) 
it is very well tolerated with modest effects on systemic 
blood pressure (e.g. dietary supplementation of inorganic 
nitrate produced an average blood pressure lowering of 
8.1/3.8 mmHg [35]).
Furthermore, recent experience in stable heart failure 
patients suggests that inorganic nitrate/nitrite supple-
mentation will be effective as a decongestive and vas-
orelaxant therapy in AHF. In stable compensated heart 
failure (NB. with preserved ejection fraction), Zamani 
et al. demonstrated in 17 patients following an acute dose 
of beetroot juice (containing 8.4 mmol inorganic nitrate), 
an increase in aerobic work capacity in a maximal supine 
cycle ergometer test, which was accompanied by a reduc-
tion in SVR, and an increase in cardiac output [36]. In 
advanced but compensated heart failure patients, the 
Frenneaux group recently reported on the central hemo-
dynamic effects of a 5-min high dose infusion of sodium 
nitrite  (NaNO2). At an infusion rate of 50  μg/kg/min, a 
12% reduction in SVR was observed, together with a 13% 
increase in cardiac output and substantial venodilation, 
with only a 4 mmHg drop in systolic blood pressure [37]. 
Whilst these short infusions did not produce any methe-
moglobinemia, a study of prolonged infusions (up to 
48 h) in healthy volunteers by Pluta et al. of ~5 μg/kg/min 
sodium nitrite did result in methemoglobinemia [38]. 
Thus, whilst intravenous sodium nitrite holds therapeutic 
promise for hemodynamic optimization in advanced HF, 
due to the limited number of studies, the safety of sus-
tained treatment in an AHF episode currently remains a 
concern.
On the other hand, oral administration of inorganic 
sodium nitrate has the advantage of having been more 
widely studied. For example, supplementation of sodium 
nitrate in the range of 5.1–45 mmol/day (321–2790 mg) 
was demonstrated to be safe in a meta-analysis of stud-
ies in hypertensive patients [39] and may therefore be a 
Fig. 1 Nitrate–nitrite–nitric oxide formation/recycle pathways. In the presence of oxygen, endothelial nitric oxide synthase (NOS) catalyzes the 
oxidation l-arginine to nitric oxide (NO). NO is oxidized to nitrite (NO−
2
) and nitrate (NO−
3
). Dietary intake of inorganic nitrate (leafy green vegetables, 
beetroot) has been shown to increase plasma nitrate, which is concentrated in saliva where is it is reduced to nitrite by commensal oral bacteria. 
Nitrite can then be absorbed and further reduced to NO via several mechanisms, under hypoxic conditions. The pools of circulating nitrate and 
nitrite are subject to renal excretion, but are also able to be recycled back to NO [52] (Source: Allen et al. [52]. (Reproduced with permission from J.D 
Allen))
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safe means of delivering the hemodynamic benefits of 
NO in AHF. Furthermore, no clinically significant methe-
moglobinemia (defined by levels ≥5%) has been demon-
strated to occur at this dose [40, 41].
Methods and design
This study is considered a pilot and feasibility study [42]. 
It is a single-center, double blind, placebo-controlled, 
randomized trial evaluating inorganic sodium nitrate 
versus placebo. The trial will be conducted at two hos-
pital campuses (Footscray Hospital and Sunshine Hos-
pital) within the Western Health hospital network, in 
metropolitan Melbourne, Australia. The trial is funded 
by a grant from the University of Melbourne. The pro-
tocol conforms to the SPIRIT 2013 statement, and the 
CONSORT-EHEALTH checklist. An overview of the 
trial design is presented in Fig. 2. The trial is registered 
with the Australian New Zealand Clinical Trials Registry 
(ACTRN12616000951459).
Aims and hypotheses
The aim of this study is to evaluate the feasibility of inor-
ganic sodium nitrate administration, using a single dose 
(8.4  mmol) and to gain an indication of its effects as a 
vasoactive treatment for AHF, via bioconversion to NO 
precursors.
Primary hypothesis
Supplemental sodium nitrate in comparison to placebo 
will result in (a) increased plasma nitrite levels (as a sur-
rogate for a circulating potential NO pool) in parallel 
with (b) improved vasorelaxation, as assessed by SVR.
Secondary hypotheses
Supplemental sodium nitrate in comparison to placebo 
will result in:
  • reduced arterial stiffness, as assessed by augmenta-
tion pressure (AP) and augmentation index (AI);
  • preserved/improved renal function, as assessed by 
serial plasma cystatin C levels;
  • no clinically significant elevation of systemic meth-
emoglobin levels, i.e. not exceeding 5%;
  • greater dyspnea relief as per the Likert scale;
  • greater systemic oxygenation as determined by arte-
rial oxygen saturation as assessed by pulse oximetry;
  • improved plasma troponin and B-type natriuretic 
peptide (BNP) concentrations;
  • reduced hospital length of stay (LOS) and incidence 
of clinical deterioration and complications of treat-
ment, including WRF, progression to respiratory fail-




Eligible subjects will be ≥18  years who present to hos-
pital within the previous 24 h with AHF and underlying 
HF with reduced ejection fraction (HFrEF), diagnosed on 
the basis of at least one symptom (dyspnea, orthopnea or 
edema) and one sign (chest crackles, peripheral edema, 
ascites) and/or radiological confirmation of pulmonary 
vascular congestion on a chest X-ray (CXR). Both the 
Boston criteria [43] and plasma BNP concentrations 
(>100 pg/mL) will be used to independently confirm (or 
refute) the AHF diagnosis. The diagnosis of HFrEF will 
be based on the European Society of Cardiology Guide-
lines [3] and adjudicated by the study cardiologist (CN). 
In order to minimize the risk of serious hypotension in 
this study, it will be required that the patient must have 
a baseline systolic blood pressure of ≥110  mmHg at 
enrolment.
Exclusion criteria
Patients will be excluded if they have a pre-existing and 
ongoing need for either inotrope therapy or organic 
nitrates. Patients will be ineligible for enrollment if they 
have an estimated glomerular filtration rate (eGFR) 
<20 mL/min/1.73 m2 or are receiving renal replacement 
therapy (dialysis). The following concomitant conditions 
will represent further exclusion criteria: anemia with a 
hemoglobin of less than 10.0 g/dL, critical aortic steno-
sis, acute severe ischaemia, isolated severe right sided 
heart failure, respiratory failure, cirrhosis of the liver 
(Child–Pugh class C) and uncontrolled heart rate (tach-
ycardia or unaddressed bradycardia), advanced malig-
nancy or advanced dementia. Women of child-bearing 
potential or nursing mothers will also be excluded. 
Finally, those with phosphodiesterase 5 inhibitor 
(PDE5I) use within the preceding 24 h will be excluded, 
on specific enquiry.
Randomization protocol and blinding of treatment allocation
Following informed consent and all baseline assess-
ments, eligible patients will be randomized 1:1 to 
sodium nitrate or placebo. The randomization list will 
be computer-generated by an independent statistician. 
A stratified block permuted randomization will be used 
with hospital campus as the stratification variable. The 
block size will not be disclosed to ensure concealment. 
Randomization will be enabled through a web-based 
application using  REDCap® electronic data capture tools 
hosted at the University of Melbourne. Patient enroll-
ment and random assignment will be performed by trial 
investigators. Sodium nitrate and placebo will be pack-
aged identically and labelled by the hospital pharmacy. 
Treatment assignment numbers will be logged with the 
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hospital pharmacy. Aside from the trial’s hospital phar-
macist, patients, nurses, treating clinicians, the trial 
investigators and the statistician will be blind to treat-
ment allocation.
Preparation and administration of the investigational 
product
In addition to standard care, patients will be randomly 
allocated to receive either a single dose of oral sodium 
Fig. 2 Overview of trial design
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nitrate (8.4 mmol, or 714 mg) or matching oral placebo. 
Food-grade sodium nitrate, a crystalline powder, will 
be compounded locally into white gelatin capsules. An 
identical placebo capsule will also be provided, as per 
randomization, containing an inert substance (micro-
crystalline cellulose,  Avicel®).
Techniques for outcome determination
Measurements for primary outcome determination
Measuring NO directly is inherently difficult, due to 
compound instability and short biological half-life. The 
majority of studies measure the concentration of plasma 
nitrite in order to evaluate the degree of bioconversion 
resulting from nitrate dosing. In this context, plasma 
nitrite is therefore a surrogate, reflecting the effective NO 
pool [44].
In order to assess sodium nitrate bioconversion and 
pharmacokinetics (including steady state concentra-
tions), blood sampling will occur at time points based 





and half-lives of orally administered inorganic nitrate 
[44, 45]. Blood will be drawn at 0, 1, 2, 3 and 6 h, cen-
trifuged for plasma, snap frozen in liquid nitrogen, and 
stored at −80  °C until analysis. Subsequent batched 
NO analysis (NOA) will be performed to determine 
plasma nitrate and nitrite levels. NOA will be per-
formed by chemical reduction, followed by chemi-
luminescence (Sievers NO analyzer) as previously 
described [44, 46]. An overview of the trial timeline is 
presented in Fig. 3.
In order to assess the vasomotor effects of supplemen-
tal nitrate, SVR (indexed to body surface area) will be 
serially assessed non-invasively. In order to obtain this, 
bioimpedance cardiography cardiac output measure-
ment will be performed utilizing the  PhysioFlow® device, 
together with simultaneous blood pressure [47] at 0, 3 
and 6 h.
Measurements for secondary outcome determination
  • Indices of arterial stiffness (AP and AI) will be 
derived utilizing the  SphygmoCor® device as previ-
ously described [48, 49] at 0, 3 and 6 h.
Fig. 3 Overview of trial timeline in hours
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  • Venous methemoglobin will be assayed from blood 
drawn at time points 0, 3 and 6 utilizing a standard 
blood gas analyzer.
  • Blood tests: plasma cystatin C, troponin and BNP will 
be determined at 0 and 6 h, and pre-discharge.
  • Clinical measurements: subjective dyspnea and sys-
temic oxygenation will be prospectively measured via 
the Likert scale and finger plethysmography, respec-
tively at 0, 3 and 6 h; length of stay and the incidence 
of complications (WRF, progression to respiratory 
failure, hypotension/hemodynamic compromise, 
stroke, and death) will be obtained from the medical 
record at the time of patient discharge; WRF, or acute 
kidney injury, will be specifically quantified according 
to the Kidney Disease Improving Global Outcomes 
(KDIGO) classification.
Data collection and data management
Study data will be collected and managed using  REDCap® 
electronic data capture tools hosted at the University of 
Melbourne [50].  REDCap® (Research Electronic Data 
Capture) is a secure, web-based application designed to 
support data capture for research studies, providing (1) 
an intuitive interface for validated data entry; (2) audit 
trails for tracking data manipulation and export proce-
dures; (3) automated export procedures for seamless data 
downloads to common statistical packages; and (4) pro-
cedures for importing data from external sources. Train-
ing of those who collect, check and enter study data will 
facilitate high quality data, including regular data checks 
for inconsistency and missing data between and within 
measurements. Before the start of the statistical analysis, 
a check will be performed to evaluate the correctness of 
the randomization.
Statistical methods
In this pilot and feasibility study, the sample size calcu-
lation was limited by available resources. As there is 
currently no relevant literature available to inform the 
sample size calculation on the primary outcomes in this 
vulnerable patient population, a total of 40 acute heart 
failure patients was felt to be realistic and achievable. 
Twenty patients per treatment group will allow detection 
of a moderate effect size of 0.6 between sodium nitrate 
and placebo with a power of 85% using a t test to evaluate 
the change from baseline to a post-baseline time point 
at a two-sided significance level of 0.05, assuming a cor-
relation of 0.8 between the baseline and post-baseline 
measurement. Based on the observed standard deviation 
for SVR of 296–416 (dyn s/cm5) at baseline in a total of 
40 patients reported by Kim et al. [51] and assuming the 
standard deviation will be similar after sodium nitrate 
treatment, an effect size of 0.6 corresponds to an absolute 
treatment effect of about 178–250 (dyn s/cm5) in favour 
of sodium nitrate compared to placebo, which is consid-
ered a clinically relevant improvement.
All randomized patients will be included in the analy-
sis of all outcomes. Descriptive statistics will be used to 
describe the characteristics of the sample and summarize 
the data by treatment group and overall. The primary 
outcomes plasma nitrite levels and SVR will be analyzed 
separately using a mixed effect repeated measures analy-
sis, including in the model the factors treatment group, 
time point and treatment by time interaction, while also 
accounting for baseline plasma levels, baseline by time 
interaction and the factor hospital campus. The primary 
hypothesis will be evaluated by examining the main dif-
ference between sodium nitrate and placebo as well as 
the difference between both over time. Secondary out-
comes measured will be analyzed similarly to the primary 
outcomes. If the underlying assumptions of the primary 
or secondary outcome data are violated, then either 
an appropriate transformation to allow for parametric 
methods or non-parametric (or bootstrapping) methods 
will be used. The number and percentage of patients with 
events of interest (e.g. complications) will be compared 
using the Fisher’s exact test. All tests will be two-sided.
Discussion
The combined aims of this project seek to determine the 
effects of a single dose of orally administered inorganic 
nitrate in patients with AHF. While previous research 
indicates that administration of organic nitrates, such 
as glyceryltrinitrate, can be effective at improving the 
acute hemodynamic and clinical status of patients with 
AHF, the induction of tolerance limits usefulness in 
acute practice. In contrast, we have outlined the thera-
peutic potential of inorganic nitrate for the clinical con-
text of AHF, which can be given orally and is not subject 
to the pharmacological tolerance, noting that there have 
been no recorded studies examining either the biocon-
version of inorganic nitrate, or its vascular effects, in 
this context. If oral inorganic nitrate supplementation 
is shown to enhance NO bioavailability and produce 
beneficial changes in peripheral vascular function in 
AHF, appropriately powered studies may be undertaken. 
This mechanistic translational study, therefore, has the 
potential to provide the foundation of a new strategy in 
AHF, where therapeutic options are acknowledged to be 
limited.
Abbreviations
ADMA: asymmetric dimethylarginine; AHF: acute heart failure; AI: augmenta-
tion index; AP: augmentation pressure; BNP: B-type natriuretic peptide; CI: 
cardiac index; CXR: chest X-ray; eGFR: estimated glomerular filtration rate; 
G6PD: glucose-6-phosphate dehydrogenase; Hb: hemoglobin; HR: heart rate; 
LOS: length of stay; NaNO2: sodium nitrite; NaNO3: sodium nitrate; NO: nitric 





: nitrate; PCWP: pulmonary capillary wedge pressure; 
PDE5I: phosphodiesterase 5 inhibitor; SVR: systemic vascular resistance; WRF: 
worsening renal function.
Authors’ contributions
CN conception of research. CN, JDA, MS, JS, SB, RF design of research protocol. 
CN, MS, RF drafted the manuscript. CN, MS, JDA, RF, SB edited and revised the 
manuscript. MS, RF prepared figures. All authors read and approved the final 
manuscript.
Author details
1 Western Centre for Health Research and Education, Western Health, 
Melbourne, Australia. 2 Department of Medicine-Western Health, Melbourne 
Medical School, The University of Melbourne, Melbourne, Australia. 3 Clinical 
Exercise Science Research Program, Institute of Sport Exercise and Active 
Living (ISEAL), Melbourne, Australia. 4 Melbourne School of Population 
and Global Health and Melbourne Clinical and Translational Sciences Platform 
(MCATS), Parkville, Australia. 5 Western Health Cardiology, Footscray Hospital, 
Gordon St, Locked Bag 2, Footscray, VIC 3011, Australia. 
Acknowledgements
This research will be conducted at Western Health Footscray and Sunshine 
Campuses, Melbourne, Victoria, Australia. This investigation is solely the 
responsibility of the authors and does not necessarily represent the official 
views of Western Health or the University of Melbourne.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Not applicable. This manuscript does not contain any data.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This protocol has been approved by the Melbourne Health Human Research 
Ethics Committee (HREC/15/MH/402 2015.214) on April 15th 2016. It is being 
supported by a research grant from the University of Melbourne, Melbourne, 
Australia, and is registered under The Australian New Zealand Clinical Trials 
Registry (ACTRN12616000951459).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 24 July 2016   Accepted: 24 July 2017
References
 1. Friedewald VE, Gheorghiade M, Yancy CW, Young JB, Roberts WC. The 
editor’s roundtable: acute decompensated heart failure. Am J Cardiol. 
2007;99:1560–7.
 2. Ponikowski P, Jankowska EA. Pathogenesis and clinical presentation of 
acute heart failure. Rev Esp Cardiol. 2015;68:331–7.
 3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, 
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guide-
lines for the diagnosis and treatment of acute and chronic heart failure: 
The Task Force for the diagnosis and treatment of acute and chronic 
heart failure of the European Society of Cardiology (ESC) developed with 
the special contribution of the Heart Failure Association (HFA) of the ESC. 
Eur Heart J. 2016;37:2129–200.
 4. Parrinello G, Torres D, Paterna S, di Pasquale P, Licata G. The pathophysiol-
ogy of acute heart failure: the key role of fluid accumulation. Am Heart J. 
2008;156:e19.
 5. Metra M, Felker GM, Zaca V, Bugatti S, Lombardi C, Bettari L, Voors AA, 
Gheorghiade M, Dei Cas L. Acute heart failure: multiple clinical profiles 
and mechanisms require tailored therapy. Int J Cardiol. 2010;144:175–9.
 6. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson 
LW. Clinical assessment identifies hemodynamic profiles that predict 
outcomes in patients admitted with heart failure. J Am Coll Cardiol. 
2003;41:1797–804.
 7. Fonarow GC, Corday E, Committee ASA. Overview of acutely decompen-
sated congestive heart failure (ADHF): a report from the ADHERE registry. 
Heart Fail Rev. 2004;9:179–85.
 8. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, 
Krakover R, Vered Z. The role of cardiac power and systemic vascular 
resistance in the pathophysiology and diagnosis of patients with acute 
congestive heart failure. Eur J Heart Fail. 2003;5:443–51.
 9. Burchell AE, Sobotka PA, Hart EC, Nightingale AK, Dunlap ME. Chemohy-
persensitivity and autonomic modulation of venous capacitance in the 
pathophysiology of acute decompensated heart failure. Curr Heart Fail 
Rep. 2013;10:139–46.
 10. Isbister JP. Physiology and pathophysiology of blood volume regulation. 
Transfus Sci. 1997;18:409–23.
 11. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid 
overload in acute heart failure—re-distribution and other mechanisms 
beyond fluid accumulation. Eur J Heart Fail. 2008;10:165–9.
 12. London GM, Marchais SJ, Guerin AP, Pannier B. Arterial stiffness: patho-
physiology and clinical impact. Clin Exp Hypertens. 2004;26:689–99.
 13. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, 
Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart 
failure. J Am Coll Cardiol. 2012;60:1455–69.
 14. Colombo PC, Onat D, Sabbah HN. Acute heart failure as “acute endotheli-
tis”—interaction of fluid overload and endothelial dysfunction. Eur J 
Heart Fail. 2008;10:170–5.
 15. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fon-
arow GC, Geraci SA, Horwich T, Januzzi JL, et al. 2013 ACCF/AHA guideline 
for the management of heart failure: a report of the American College 
of Cardiology Foundation/American Heart Association Task Force on 
Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.
 16. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJem-
tel TH, Cheng ML, Wynne J, Committee ASA and Investigators, Group AS. 
In-hospital mortality in patients with acute decompensated heart failure 
requiring intravenous vasoactive medications: an analysis from the Acute 
Decompensated Heart Failure National Registry (ADHERE). J Am Coll 
Cardiol. 2005;46:57–64.
 17. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham 
O, Marghitay D, Koren M, Blatt A, et al. Randomised trial of high-dose 
isosorbide dinitrate plus low-dose furosemide versus high-dose furo-
semide plus low-dose isosorbide dinitrate in severe pulmonary oedema. 
Lancet. 1998;351:389–93.
 18. Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, Blatt 
A, Simovitz A, Shaham O, Faigenberg Z, et al. High-dose intravenous 
isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined 
with conventional treatment for severe pulmonary edema. J Am Coll 
Cardiol. 2000;36:832–7.
 19. Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, Horowitz 
JD. Nitrate therapy is an alternative to furosemide/morphine therapy in 
the management of acute cardiogenic pulmonary edema. J Card Fail. 
1998;4:271–9.
 20. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation and nitrate 
tolerance: news, views and troubles. Br J Pharmacol. 2008;155:170–84.
 21. Munzel T, Steven S, Daiber A. Organic nitrates: update on mechanisms 
underlying vasodilation, tolerance and endothelial dysfunction. Vascul 
Pharmacol. 2014;63:105–13.
 22. Petersson M, Rundqvist B, Bennett BM, Adams MA, Friberg P. Impaired 
nitroglycerin biotransformation in patients with chronic heart failure. Clin 
Physiol Funct Imaging. 2008;28:229–34.
 23. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, 
Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, et al. Effects of oral 
tolvaptan in patients hospitalized for worsening heart failure: the EVER-
EST Outcome Trial. JAMA. 2007;297:1319–31.
Page 9 of 9Falls et al. J Transl Med  (2017) 15:172 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 24. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, 
Weatherley BD, Cleland JG, Givertz MM, Voors A, et al. Rolofylline, an 
adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 
2010;363:1419–28.
 25. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, 
Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, et al. Effect 
of nesiritide in patients with acute decompensated heart failure. N Engl J 
Med. 2011;365:32–43.
 26. Bart BA. Treatment of congestion in congestive heart failure: ultrafiltration 
is the only rational initial treatment of volume overload in decompen-
sated heart failure. Circ Heart Fail. 2009;2:499–504.
 27. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, 
Ponikowski P, Unemori E, Voors AA, Adams KF Jr, et al. Serelaxin, recombi-
nant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a 
randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
 28. Tietjens J, Teerlink JR. Serelaxin and acute heart failure. Heart. 
2016;102:95–9.
 29. Hermansen SE, Kalstad T, How OJ, Myrmel T. Inflammation and reduced 
endothelial function in the course of severe acute heart failure. Transl Res. 
2011;157:117–27.
 30. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Oku-
mura K. High plasma level of asymmetric dimethylarginine in patients 
with acutely exacerbated congestive heart failure: role in reduction of 
plasma nitric oxide level. Heart Vessels. 2003;18:177–82.
 31. Modin A, Bjorne H, Herulf M, Alving K, Weitzberg E, Lundberg JO. Nitrite-
derived nitric oxide: a possible mediator of ‘acidic-metabolic’ vasodilation. 
Acta Physiol Scand. 2001;171:9–16.
 32. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric 
oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 
2008;7:156–67.
 33. Dejam A, Hunter CJ, Schechter AN, Gladwin MT. Emerging role of nitrite 
in human biology. Blood Cells Mol Dis. 2004;32:423–9.
 34. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G, Partovi K, 
Pelletier MM, Oldfield EH, Cannon RO 3rd, et al. Nitrite infusion in humans 
and nonhuman primates: endocrine effects, pharmacokinetics, and toler-
ance formation. Circulation. 2007;116:1821–31.
 35. Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary 
nitrate provides sustained blood pressure lowering in hypertensive 
patients: a randomized, phase 2, double-blind, placebo-controlled study. 
Hypertension. 2015;65:320–7.
 36. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias 
PT, Ischiropoulos H, Townsend RR, Margulies KB, et al. Effect of inorganic 
nitrate on exercise capacity in heart failure with preserved ejection frac-
tion. Circulation. 2015;131:371–80 (discussion 380).
 37. Ormerod JO, Arif S, Mukadam M, Evans JD, Beadle R, Fernandez BO, 
Bonser RS, Feelisch M, Madhani M, Frenneaux MP. Short-term intravenous 
sodium nitrite infusion improves cardiac and pulmonary hemodynamics 
in heart failure patients. Circ Heart Fail. 2015;8:565–71.
 38. Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, 
Nahavandi M, Woo S, Figg WD, Lonser RR. Safety and feasibility of long-
term intravenous sodium nitrite infusion in healthy volunteers. PLoS ONE. 
2011;6:e14504.
 39. Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and 
beetroot juice supplementation reduces blood pressure in adults: a 
systematic review and meta-analysis. J Nutr. 2013;143:818–26.
 40. Lambers AC, Koppeschaar HPF, van Isselt JW, Slob W, Schothorst RC, 
Mensinga TT, Meulenbelt J. The effect of nitrate on the thyroid gland 
function in healthy volunteers in a 4-week oral toxicity study. RIVM 
National Institute for Public Health and the Environment, Netherlands; 
2000.
 41. Nitrite (WHO Food Additive Series 35). http://www.inchem.org/docu-
ments/jecfa/jecmono/v35je13.htm. Accessed 07 July 2016.
 42. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Cole-
man CL, Bond CM. Defining feasibility and pilot studies in preparation for 
randomised controlled trials: development of a conceptual framework. 
PLoS ONE. 2016;11:e0150205.
 43. Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, 
Budner N, Lense L, Wachspress J. The relationship between left ventricular 
systolic function and congestive heart failure diagnosed by clinical crite-
ria. Circulation. 1988;77:607–12.
 44. Woessner M, Smoliga JM, Tarzia B, Stabler T, Van Bruggen M, Allen JD. 
A stepwise reduction in plasma and salivary nitrite with increasing 
strengths of mouthwash following a dietary nitrate load. Nitric Oxide. 
2016;54:1–7.
 45. Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, 
Arghandawi S, Pearl V, Benjamin N, Loukogeorgakis S, et al. Inorganic 
nitrate supplementation lowers blood pressure in humans: role for 
nitrite-derived NO. Hypertension. 2010;56:274–81.
 46. Allen JD, Stabler T, Kenjale AA, Ham KL, Robbins JL, Duscha BD, Kraus WE, 
Annex BH. Diabetes status differentiates endothelial function and plasma 
nitrite response to exercise stress in peripheral arterial disease following 
supervised training. J Diabetes Complicat. 2014;28:219–25.
 47. Tonelli AR, Alkukhun L, Arelli V, Ramos J, Newman J, McCarthy K, Pichurko 
B, Minai OA, Dweik RA. Value of impedance cardiography during 6-min 
walk test in pulmonary hypertension. Clin Transl Sci. 2013;6:474–80.
 48. Chen CH, Nevo E, Fetics B, Pak PH, Yin FCP, Maughan WL, Kass DA. Estima-
tion of central aortic pressure waveform by mathematical transformation 
of radial tonometry pressure—validation of generalized transfer function. 
Circulation. 1997;95:1827–36.
 49. Allen JD, Robbins JL, Vanbruggen MD, Credeur DP, Johannsen NM, 
Earnest CP, Pieper CF, Johnson JL, Church TS, Ravussin E, et al. Unlocking 
the barriers to improved functional capacity in the elderly: rationale and 
design for the “Fit for Life trial”. Contemp Clin Trials. 2013;36:266–75.
 50. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research 
electronic data capture (REDCap)—a metadata-driven methodology and 
workflow process for providing translational research informatics sup-
port. J Biomed Inform. 2009;42:377–81.
 51. Kim BG, Cho SW, Lee HY, Kim DH, Byun YS, Goh CW, Rhee KJ, Kim BO. 
Reduced systemic vascular resistance is the underlying hemodynamic 
mechanism in nitrate-stimulated vasovagal syncope during head-up tilt-
table test. J Arrhythm. 2015;31:196–200.
 52. Allen JD, Giordano T, Kevil CG. Nitrite and nitric oxide metabolism in 
peripheral artery disease. Nitric Oxide. 2012;26:217–22.
